⌕
Mineralys Therapeutics · MLYS · Nasdaq
Tenet 55 · Mixed
Compare
$14.48−0.34%At closeTenet 55 · Mixed
$14.48−0.05 (−0.34%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Mineralys Therapeutics (MLYS) Institutional Ownership

13F filers reported holding 40.4% of Mineralys Therapeutics (MLYS) shares as of Sep 30, 2026, across 116 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
40.4%
Sep 30, 2026
13F filers
116
quarter ended Sep 30, 2026
13F value
$900.0M
35.8M shares
Quarter's fund flow
Mild accumulation
21 new · 11 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (21 new · 51 increased · 26 reduced · 11 closed · 7 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 116 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 19, 2026COATS LONNELdirectorAcquired · Grant / award12,400—↗
Oct 19, 2026COATS LONNELdirectorAcquired · Grant / award16,600Stock Option—↗
Oct 19, 2026Peterson KristinedirectorAcquired · Grant / award12,400—↗
Oct 19, 2026Peterson KristinedirectorAcquired · Grant / award16,600Stock Option—↗
Sep 30, 2026Congleton JonChief Executive OfficerDisposed · Open-market sale75,000$25.46↗
Sep 22, 2026Slingsby Brian TaylordirectorDisposed · Open-market sale104,320$28.81↗
Sep 21, 2026Warren EricChief Commercial OfficerAcquired · Option exercise7,438$13.24↗
Sep 21, 2026Warren EricChief Commercial OfficerDisposed · Open-market sale7,438$28.12↗
Sep 21, 2026Warren EricChief Commercial OfficerDisposed · Option exercise7,438Stock Option—↗
Sep 15, 2026Karydas DaphnedirectorAcquired · Option exercise3,000$12.02↗
Sep 15, 2026Karydas DaphnedirectorDisposed · Open-market sale3,000$28.58↗
Sep 15, 2026Karydas DaphnedirectorDisposed · Option exercise3,000Stock Option—↗
Aug 21, 2026Warren EricChief Commercial OfficerAcquired · Option exercise7,437$13.24↗
Aug 21, 2026Warren EricChief Commercial OfficerDisposed · Open-market sale7,437$25.98↗
Aug 21, 2026Warren EricChief Commercial OfficerDisposed · Option exercise7,437Stock Option—↗
Aug 10, 2026Ferguson James J. IIIChief Medical OfficerAcquired · Grant / award102,400—↗
Aug 10, 2026Ferguson James J. IIIChief Medical OfficerAcquired · Grant / award135,000Stock Option—↗
Aug 10, 2026Rodman David MalcomChief Medical OfficerAcquired · Option exercise2,170$16.00↗
Aug 10, 2026Rodman David MalcomChief Medical OfficerDisposed · Open-market sale2,170$27.09↗
Aug 10, 2026Rodman David MalcomChief Medical OfficerDisposed · Option exercise2,170Stock Option—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Mineralys Therapeutics do institutions hold?

13F filers reported holding 40.4% of Mineralys Therapeutics' shares as of Sep 30, 2026, across 116 filers.

How many 13F filers hold Mineralys Therapeutics?

Mineralys Therapeutics was held by 116 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.